- cafead Oct 08, 2018 at 11:12: PM
via Last week, Eli Lilly unveiled positive data for a new diabetes drug with serious potential to disrupt the GLP-1 market. But its rivals don't need to hunker down, analysts said.
At the European Association for the Study of Diabetes annual meeting, the Indianapolis drugmaker presented phase 2b results showing its dual GIP and GLP-1 receptor agonist, known for now as GIP/GLP-1 RA, could significantly reduce blood sugar and increase weight loss.
article source
At the European Association for the Study of Diabetes annual meeting, the Indianapolis drugmaker presented phase 2b results showing its dual GIP and GLP-1 receptor agonist, known for now as GIP/GLP-1 RA, could significantly reduce blood sugar and increase weight loss.
article source